Search
Lorpiprazole
go.drugbank.com/drugs/DB09195ApprovedLorpiprazole is a serotonin antagonist and reuptake inhibitor used for the treatment of major depressive disorder. It is a piperazinyl-triazole derivative.
Collagenase clostridium histolyticum
go.drugbank.com/drugs/DB00048ApprovedInvestigational[L14912] On July 6, 2020 a combination of injectable bacterial collagenases was approved by the FDA for the treatment of cellulite in adult women. … [L14872] Also known as Qwo, this injection is the first approved injectable treatment for cellulite and was developed by Endo International.[L14892]
Ubrogepant
go.drugbank.com/drugs/DB15328ApprovedInvestigational[erenumab], [fremanezumab], [galcanezumab]) have also been approved in recent years.[A189207] Ubrogepant was approved by Health Canada on November 10, 2022. … [L10926] It was approved by the FDA on December 23, 2019, and is the first oral calcitonin gene-related peptide (CGRP) receptor antagonist approved for the acute treatment of migraine.
Scopolamine
go.drugbank.com/drugs/DB00747ApprovedInvestigational[A228758, L31578] Due to its dose-dependent adverse effects, scopolamine was the first drug to be offered commercially as a transdermal delivery system, Scopoderm TTS®, in 1981. … [A228773, L31578] Scopolamine was first approved by the FDA on December 31, 1979, and is currently available as both oral tablets and a transdermal delivery system.[L31578]
Sutimlimab
go.drugbank.com/drugs/DB14996ApprovedInvestigational[L40114,A245144] Sutimlimab was also approved by the European Commission in November 2022.[L44116] … [A245159] Pharmacologic strategies have included the targeting of B-cells with agents like [rituximab], as well as targeting of the complement system with drugs like [eculizumab], an anti-C5 mAb, and [
Strontium ranelate
go.drugbank.com/drugs/DB09267ApprovedWithdrawnAvailable for prescription use for a time in some parts of the world as Protelos (strontium ranelate) 2 g granules for oral suspension by Servier, it was ultimately discontinued in 2016-2017 owing to an … It is therefore promoted as a "dual action bone agent" (DABA) indicated for use in treatment of severe osteoporosis.
Padeliporfin
go.drugbank.com/drugs/DB15575ApprovedInvestigational[A244699] Padeliporfin was first approved by the European Commission on November 10, 2017, for the treatment of low-risk prostate cancer in adults meeting certain clinical criteria.[L39799]
Categories: Sensitizers Used in Photodynamic/radiation TherapyInfluenza A virus A/Christchurch/16/2010 NIB-74 (H1N1) antigen (propiolactone inactivated)
go.drugbank.com/drugs/DB10781ApprovedWithdrawnInactivated vaccines contain a virus particle that has been grown in media and then subsequently killed, or inactivated, through exposure to heat or chemicals such as formaldehyde 3. … that it was previously exposed to.
Mixtures: Physicians EZ Use Flu Kit, Medical Provider Single Use EZ Flu Shot KitMethohexital
go.drugbank.com/drugs/DB00474ApprovedAn intravenous anesthetic with a short duration of action that may be used for induction of anesthesia.
Relugolix
go.drugbank.com/drugs/DB11853ApprovedInvestigational[L27991,L27996] This branded product was later approved by the European Commission on April 29, 2022.[L42150] Relugolix has also been studied in the symptomatic treatment of endometriosis. … It was first approved in Japan in 2019, under the brand name Relumina, for the symptomatic treatment of uterine fibroids,[A225816] and more recently by the United States' FDA in 2020, under the brand name